Catalyst Financial Partners LLC Acquires Shares of 2,071 DexCom, Inc. (NASDAQ:DXCM)

Catalyst Financial Partners LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 2,071 shares of the medical device company’s stock, valued at approximately $257,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sands Capital Management LLC boosted its stake in shares of DexCom by 4.3% during the 3rd quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock worth $1,274,541,000 after purchasing an additional 557,543 shares during the period. Blair William & Co. IL boosted its holdings in DexCom by 1.7% during the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock valued at $420,517,000 after acquiring an additional 73,654 shares during the period. Northern Trust Corp grew its position in DexCom by 2.4% in the 3rd quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock valued at $363,545,000 after acquiring an additional 91,249 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in DexCom by 3.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,241,701 shares of the medical device company’s stock worth $278,173,000 after purchasing an additional 80,740 shares during the period. Finally, Winslow Capital Management LLC bought a new stake in shares of DexCom during the third quarter worth $173,120,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of research analyst reports. Citigroup upped their price target on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. UBS Group boosted their price target on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Royal Bank of Canada began coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. Finally, Raymond James lifted their target price on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $141.67.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the sale, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the sale, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Jon Brown sold 2,624 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the transaction, the executive vice president now owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 190,004 shares of company stock worth $25,610,270. 0.41% of the stock is owned by insiders.

DexCom Stock Down 2.1 %

Shares of NASDAQ DXCM traded down $2.68 during trading hours on Wednesday, hitting $127.42. 1,336,567 shares of the stock were exchanged, compared to its average volume of 2,981,269. The company has a market cap of $50.67 billion, a PE ratio of 82.21, a PEG ratio of 2.19 and a beta of 1.23. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The firm has a fifty day moving average price of $132.94 and a 200-day moving average price of $121.16.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. On average, sell-side analysts expect that DexCom, Inc. will post 1.78 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.